Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Alligator Bioscience AB (Nasdaq Stockholm: ATORX)

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. *


Period Start 2000-12-01 established
  Group Alligator Bioscience (Group)
  Predecessor University of Lund (Lund University)
Products Industry FIND® technology (Fragment INduced Diversity)
  Industry 2 mitazalimab (ADC-1013)
Persons Person Norlén, Per (Alligator Bioscience –202103 CEO)
  Person 2 Benson, Peter (Sunstone Capital 200705– Managing Partner Life Science Ventures)
Region Region Lund
  Country Sweden
  City 223 81 Lund
  Tel +46-46-286-4280
    Address record changed: 2020-12-02
Basic data Employees C: 51 to 100 (2019-12-31)
  Currency SEK
  Annual sales 4,352,000 (sales, net, consolidated (2020) 2020-12-31)
  Profit -143,296,000 (2020-12-31)
  Cash 103,342,000 (2020-12-31)
    * Document for �About Section�: Alligator Bioscience AB. (1/18/18). "Press Release: Alligator Bioscience Appoints New VP Business Development". Lund.
Record changed: 2021-04-19


Picture [iito] Made Without Love 650x80px

More documents for Alligator Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top